Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study

Paul W. Jones, Dave Singh, Eric D. Bateman, Alvar Agusti, Rosa Lamarca, Gonzalo de Miquel, Rosa Segarra, Cynthia Caracta, Esther Garcia Gil
European Respiratory Journal 2012; DOI: 10.1183/09031936.00225511
Paul W. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pjones@sgul.ac.uk
Dave Singh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric D. Bateman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alvar Agusti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Lamarca
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gonzalo de Miquel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Segarra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Caracta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Garcia Gil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The efficacy and safety of two doses of aclidinium bromide were evaluated in patients with moderate to severe COPD.

In this 24-week, double-blind trial, patients were randomised to twice-daily aclidinium (200 μg or 400 μg) or placebo. The primary efficacy endpoint was change in trough forced expiratory volume in 1 second (FEV1) at Week 24. Other endpoints included peak FEV1, health status (St George's Respiratory Questionnaire; SGRQ) and dyspnoea (Transitional Dyspnoea Index; TDI).

Overall, 828 patients were randomised. At Week 24, significant improvements from baseline were observed with aclidinium 200 μg and 400 μg versus placebo for trough FEV1 (99 and 128 mL; both p<0.0001) and peak FEV1 (185 and 209 mL; both p<0.0001). Peak FEV1 improvements on Day 1 were comparable with Week 24. Aclidinium 200 μg and 400 μg produced significant improvements over placebo in baseline-adjusted mean SGRQ total score (−3.8 and −4.6 units; p<0.001 and <0.0001) and TDI focal score (0.6 and 1.0 units; p<0.05 and <0.001) at Week 24. With both aclidinium doses, the incidence of anticholinergic adverse events was low and similar to placebo.

Twice-daily aclidinium significantly improved bronchodilation, health status and dyspnoea, and was well tolerated in patients with COPD.

  • Anticholinergic
  • bronchodilation
  • dyspnoea
  • exacerbations
  • health status
  • long-acting muscarinic antagonist
  • ERS
Next
Back to top
Vol 61 Issue 3 Table of Contents
European Respiratory Journal: 61 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study
Paul W. Jones, Dave Singh, Eric D. Bateman, Alvar Agusti, Rosa Lamarca, Gonzalo de Miquel, Rosa Segarra, Cynthia Caracta, Esther Garcia Gil
European Respiratory Journal Jan 2012, erj02255-2011; DOI: 10.1183/09031936.00225511

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study
Paul W. Jones, Dave Singh, Eric D. Bateman, Alvar Agusti, Rosa Lamarca, Gonzalo de Miquel, Rosa Segarra, Cynthia Caracta, Esther Garcia Gil
European Respiratory Journal Jan 2012, erj02255-2011; DOI: 10.1183/09031936.00225511
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Lung volumes and survival in chronic lung allograft dysfunction
  • Aspergillus fumigatus in COPD
  • Calcineurin inhibitors in bronchiolitis obliterans syndrome
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society